Skip to main content
R
NeighborhoodReport

Northyards Blvd

Atlanta, GA 30313 Luxury
3
Homes
1
Streets
$23,259,067
Avg Home

Address Directory

1 384 Northyards Blvd Nw

Owner: Mcp Northyards Owner LLC
PPP $368,398 4 vehicles 4 businesses Gov Contract Fed Grant Nonprofit EPA Facility
$63,661,300
View on Zillow →

2 385 Northyards Blvd Nw

Owner: Taylor Letter Service INC
Officer - Taylor Letter Service, INC. 1 business
$1,450,000
View on Zillow →

3 395 Northyards Blvd Nw

Owner: Vlp 4 LLC
$4,665,900
View on Zillow →

Source: County assessor records, public records & state business filings · Updated Feb 2026

Loading map...

Commercial Fleet Presence

FMCSA Motor Carrier Registry

Heavy
36
Carriers
172
Power Units
286
Drivers
4.8
Avg Fleet
For-Hire: 29
Private: 7
Largest Carriers in ZIP
U-HAUL
DOT #428379 · Interstate
83 units
150 drivers
LOCS OF LUXEY LLC
DOT #4018659 · Interstate
26 units
28 drivers
TRAYVICK LLC
DOT #4330396 · Intrastate
17 units
4 drivers
SK LOGISTICS LLC
DOT #3841241 · Intrastate
6 units
12 drivers
H & H DEMOLITION INC
DOT #785418 · Intrastate
4 units
3 drivers

36 registered motor carriers in this ZIP. operating 172 power units. 29 for-hire carriers.

Explore Nearby in Atlanta

Discover other neighborhoods in Atlanta, GA and compare what they have to offer.

EPA Regulated Facilities

EPA Facility Registry Service

Very High
247
< 1 Mile
500
< 3 Miles
500
< 5 Miles
High
Concern
Facility Categories
💨 Air Emissions 61 Hazardous Waste 41 Superfund 9 Toxic Release 3 🏚 Brownfields 11 💧 Water Discharge 5 🛢 Underground Storage 1 🏛 Federal Facilities 10 🚰 Water Systems 1
Facilities of Concern
HERNDON HOMES
SUPERFUND (NON-NPL)
0.17 mi
JETT STREET DRUMS
SUPERFUND (NON-NPL)
0.27 mi
ABRAMS FIXTURE CORP J
AIR MAJOR
0.31 mi
WESTSIDE LEAD
FORMAL ENFORCEMENT ACTION, SUPERFUND NPL
0.32 mi
COCA COLA NORTH AMERICA
AIR MINOR, HAZARDOUS WASTE BIENNIAL REPORTER, LQG
0.4 mi

500 EPA-regulated facilities within 5 miles. 247 within 1 mile. 9 Superfund sites. 3 toxic release reporters. 41 hazardous waste generators. 1 water systems serve the area.

Federal Grants & Assistance

USAspending.gov grant awards to recipients in this neighborhood.

8 grant records found FY2024–2025
Exvade Bioscience INC
380 Northyards Blvd Nw
Department of Health and Human Services / National Institutes of Health
CANCER DETECTION AND DIAGNOSIS RESEARCH
TUMOR MONORAIL DEVICE FOR SERIAL GLIOBLASTOMA BIOPSY - PROJECT SUMMARY/ABSTRACT GLIOBLASTOMA (GBM) IS ONE OF THE MOST COMMON AND DEADLIEST FORM OF MALIGNANT BRAIN TUMORS, WITH MEDIAN PATIENT SURVIVAL OF 12-15 MONTHS AND FIVE-YEAR SURVIVAL OF LESS THAN 5%. THE CURRENT STANDARD OF THERAPY FOR GBM COMPRISES SURGICAL RESECTION THEN RADIATION AND CHEMOTHERAPY. HOWEVER, DUE TO THE HETEROGENEITY AND INVASIVE NATURE OF GBM TUMOR CELLS THERE IS A HIGH RATE (~80%) OF TUMOR RECURRENCE, LEADING TO DISMAL SURVIVAL RATES THAT HAVE NOT CHANGED SIGNIFICANTLY IN OVER 50 YEARS. ONE OF THE PRIMARY HURDLES TO IMPROVING THESE OUT- COMES IS THE LACK OF RELIABLE AND ACCURATE MEANS TO MONITOR TUMOR PROGRESSION AND TREATMENT RESPONSE. THE CURRENT STANDARD METHODS OF TUMOR MONITORING, DIRECT TISSUE BIOPSY AND EXTERNAL IMAGING, ARE NOT ABLE TO SAFELY PROVIDE ACCURATE, FOCAL, LONGITUDINAL INFORMATION ABOUT THE TUMOR PROGRESSION AND TREATMENT RESPONSE THAT WOULD ALLOW CLINICIANS TO MODIFY TREATMENT REGIMEN TO IMPROVE SURVIVAL OUTCOMES. HERE WE PROPOSE THE TUMOR MONORAIL AS A PLATFORM THAT ALLOWS DIRECT, SERIAL ACCESS TO TUMOR MATERIAL, PROVIDING CRITICAL INFORMATION ABOUT TUMORS IN REAL TIME THAT WILL HELP CLINICIANS IMPROVE ACTIVE TREATMENT MANAGEMENT AND PATIENT SURVIVAL. THE TUMOR MONORAIL IS A BREAKTHROUGH DESIGNATED DEVICE AND HAS BEEN THE SUBJECT OF MULTIPLE FDA PRE-SUB- MISSION MEETINGS AND EXTENSIVE VERIFICATION AND BIOCOMPATIBILITY TESTING. BY LEVERAGING DESIGN AND MATERIAL SE- LECTIONS WITH A LONG HISTORY OF SAFE CLINICAL USE, THE TUMOR MONORAIL CAN SAFELY PROVIDE ACCESS TO THIS TYPICALLY INACCESSIBLE TUMOR IN AN OUTPATIENT SETTING. THIS WILL PROVIDE CLINICIANS WITH AN UNPRECEDENTED AMOUNT OF INFOR- MATION ABOUT TUMOR GENETICS AND TREATMENT RESPONSE IN REAL TIME THAT IS CRITICALLY IMPORTANT TO IMPROVING OUT- COMES FOR THE TREATMENT OF GBM. THE POTENTIAL IMPACT OF THIS PARADIGM SHIFTING DIAGNOSTIC TOOL IS WIDE RANGING, INCLUDING ENHANCING THE EFFICACY OF CURRENT STANDARD OF CARE AND NOVEL TREATMENT REGIMENS, INCREASING CLINICAL TRIAL EFFICIENCY BY ACCELERATING PATIENT PLACEMENT AND DATA COLLECTION, REMOVING UNCERTAINTY ABOUT TREATMENT EFFI- CACY AND TUMOR PROGRESSION INHERENT IN IMAGING, AND MORE. THE AIMS OF THIS PROPOSAL ARE FOCUSED ON OPTIMIZATION AND CLINICAL TRANSLATION OF THE TUMOR MONORAIL AS A PLAT- FORM FOR LONGITUDINAL GBM SAMPLING. IN THE PHASE 1 PORTION OF THE PROPOSAL WE WILL FIRST OPTIMIZE THE SAMPLING ABILITY AND CELLULAR MIGRATION IN THE DEVICE AND PERFORM MULTIPLE PRE-CLINICAL VERIFICATION TESTS THAT WILL IMPROVE USABILITY AND EASE REGULATORY APPROVAL. IN THE PHASE II PORTION WE WILL VALIDATE THE DEVICE EFFICACY IN CONCERT WITH STANDARD OF CARE TREATMENT IN A RODENT MODEL AND PERFORM MORE FDA REQUESTED PRE-CLINICAL TESTING THAT WILL CONFIRM LONG TERM EXPLANTABILITY, CLINICAL USABILITY, AND PREPARATION OF THE DEVICE FOR RAPID CLINICAL TRANSLATION. THESE ACTIVITIES WILL ENSURE THAT THE TUMOR MONORAIL IS WELL POSITIONED FOR SUBMISSION OF AN INVESTIGATIONAL DE- VICE EXEMPTION (IDE), CLINICAL TRANSLATION, AND RAPID ADOPTION TO PROVIDE A NEW TREATMENT PATH FOR GBM FOCUSED ON ACTIVE DISEASE MANAGEMENT AND INDIVIDUALLY TARGETED, RESPONSIVE TREATMENT THAT WOULD ALLOW CLINICIANS TO TAILOR INTERVENTIONS IN REAL TIME, INCREASING PATIENT OUTCOMES THAT HAVE BEEN STAGNANT FOR DECADES.
$2,397,615
PROJECT GRANT (B)
Sep 10, 2024
Exvade Bioscience INC
380 Northyards Blvd Nw
Department of Health and Human Services / National Institutes of Health
CANCER DETECTION AND DIAGNOSIS RESEARCH
TUMOR MONORAIL DEVICE FOR SERIAL GLIOBLASTOMA BIOPSY - PROJECT SUMMARY/ABSTRACT GLIOBLASTOMA (GBM) IS ONE OF THE MOST COMMON AND DEADLIEST FORM OF MALIGNANT BRAIN TUMORS, WITH MEDIAN PATIENT SURVIVAL OF 12-15 MONTHS AND FIVE-YEAR SURVIVAL OF LESS THAN 5%. THE CURRENT STANDARD OF THERAPY FOR GBM COMPRISES SURGICAL RESECTION THEN RADIATION AND CHEMOTHERAPY. HOWEVER, DUE TO THE HETEROGENEITY AND INVASIVE NATURE OF GBM TUMOR CELLS THERE IS A HIGH RATE (~80%) OF TUMOR RECURRENCE, LEADING TO DISMAL SURVIVAL RATES THAT HAVE NOT CHANGED SIGNIFICANTLY IN OVER 50 YEARS. ONE OF THE PRIMARY HURDLES TO IMPROVING THESE OUT- COMES IS THE LACK OF RELIABLE AND ACCURATE MEANS TO MONITOR TUMOR PROGRESSION AND TREATMENT RESPONSE. THE CURRENT STANDARD METHODS OF TUMOR MONITORING, DIRECT TISSUE BIOPSY AND EXTERNAL IMAGING, ARE NOT ABLE TO SAFELY PROVIDE ACCURATE, FOCAL, LONGITUDINAL INFORMATION ABOUT THE TUMOR PROGRESSION AND TREATMENT RESPONSE THAT WOULD ALLOW CLINICIANS TO MODIFY TREATMENT REGIMEN TO IMPROVE SURVIVAL OUTCOMES. HERE WE PROPOSE THE TUMOR MONORAIL AS A PLATFORM THAT ALLOWS DIRECT, SERIAL ACCESS TO TUMOR MATERIAL, PROVIDING CRITICAL INFORMATION ABOUT TUMORS IN REAL TIME THAT WILL HELP CLINICIANS IMPROVE ACTIVE TREATMENT MANAGEMENT AND PATIENT SURVIVAL. THE TUMOR MONORAIL IS A BREAKTHROUGH DESIGNATED DEVICE AND HAS BEEN THE SUBJECT OF MULTIPLE FDA PRE-SUB- MISSION MEETINGS AND EXTENSIVE VERIFICATION AND BIOCOMPATIBILITY TESTING. BY LEVERAGING DESIGN AND MATERIAL SE- LECTIONS WITH A LONG HISTORY OF SAFE CLINICAL USE, THE TUMOR MONORAIL CAN SAFELY PROVIDE ACCESS TO THIS TYPICALLY INACCESSIBLE TUMOR IN AN OUTPATIENT SETTING. THIS WILL PROVIDE CLINICIANS WITH AN UNPRECEDENTED AMOUNT OF INFOR- MATION ABOUT TUMOR GENETICS AND TREATMENT RESPONSE IN REAL TIME THAT IS CRITICALLY IMPORTANT TO IMPROVING OUT- COMES FOR THE TREATMENT OF GBM. THE POTENTIAL IMPACT OF THIS PARADIGM SHIFTING DIAGNOSTIC TOOL IS WIDE RANGING, INCLUDING ENHANCING THE EFFICACY OF CURRENT STANDARD OF CARE AND NOVEL TREATMENT REGIMENS, INCREASING CLINICAL TRIAL EFFICIENCY BY ACCELERATING PATIENT PLACEMENT AND DATA COLLECTION, REMOVING UNCERTAINTY ABOUT TREATMENT EFFI- CACY AND TUMOR PROGRESSION INHERENT IN IMAGING, AND MORE. THE AIMS OF THIS PROPOSAL ARE FOCUSED ON OPTIMIZATION AND CLINICAL TRANSLATION OF THE TUMOR MONORAIL AS A PLAT- FORM FOR LONGITUDINAL GBM SAMPLING. IN THE PHASE 1 PORTION OF THE PROPOSAL WE WILL FIRST OPTIMIZE THE SAMPLING ABILITY AND CELLULAR MIGRATION IN THE DEVICE AND PERFORM MULTIPLE PRE-CLINICAL VERIFICATION TESTS THAT WILL IMPROVE USABILITY AND EASE REGULATORY APPROVAL. IN THE PHASE II PORTION WE WILL VALIDATE THE DEVICE EFFICACY IN CONCERT WITH STANDARD OF CARE TREATMENT IN A RODENT MODEL AND PERFORM MORE FDA REQUESTED PRE-CLINICAL TESTING THAT WILL CONFIRM LONG TERM EXPLANTABILITY, CLINICAL USABILITY, AND PREPARATION OF THE DEVICE FOR RAPID CLINICAL TRANSLATION. THESE ACTIVITIES WILL ENSURE THAT THE TUMOR MONORAIL IS WELL POSITIONED FOR SUBMISSION OF AN INVESTIGATIONAL DE- VICE EXEMPTION (IDE), CLINICAL TRANSLATION, AND RAPID ADOPTION TO PROVIDE A NEW TREATMENT PATH FOR GBM FOCUSED ON ACTIVE DISEASE MANAGEMENT AND INDIVIDUALLY TARGETED, RESPONSIVE TREATMENT THAT WOULD ALLOW CLINICIANS TO TAILOR INTERVENTIONS IN REAL TIME, INCREASING PATIENT OUTCOMES THAT HAVE BEEN STAGNANT FOR DECADES.
$2,397,615
PROJECT GRANT (B)
Sep 2, 2025
Hands On Atlanta, INC.
384 Northyards Blvd Nw
Corporation for National and Community Service
AMERICORPS MARTIN LUTHER KING JR. DAY OF SERVICE GRANTS 94.014
THIS AWARD APPROVES FUNDING FOR THE 2025?2026 MARTIN LUTHER KING JR. DAY OF SERVICE PROGRAM DESCRIBED IN THE APPROVED PROGRAM NARRATIVE AND BUDGET. YOUR 2025-2026 REGULATORY MATCH IS 70%, AND YOUR BUDGETARY MATCH IS 70.58%.
$300,020
PROJECT GRANT (B)
Sep 25, 2025
Hands On Atlanta, INC.
384 Northyards Blvd Nw
Corporation for National and Community Service
AMERICORPS MARTIN LUTHER KING JR. DAY OF SERVICE GRANTS 94.014
THIS AWARD APPROVES FUNDING FOR THE 2024?2025 MARTIN LUTHER KING JR. DAY OF SERVICE PROGRAM DESCRIBED IN THE APPROVED PROGRAM NARRATIVE AND BUDGET. YOUR 2024-2025 REGULATORY MATCH IS 70%, AND YOUR BUDGETARY MATCH IS 71.05%. THIS AWARD ALSO REMOVES THE SPECIAL CONDITION PLACED ON AMENDMENT 1.
$300,020
PROJECT GRANT (B)
Aug 29, 2024
Exvade Bioscience INC
380 Northyards Blvd Nw
Department of Health and Human Services / National Institutes of Health
CANCER DETECTION AND DIAGNOSIS RESEARCH
TUMOR MONORAIL DEVICE FOR SERIAL GLIOBLASTOMA BIOPSY - PROJECT SUMMARY/ABSTRACT GLIOBLASTOMA (GBM) IS ONE OF THE MOST COMMON AND DEADLIEST FORM OF MALIGNANT BRAIN TUMORS, WITH MEDIAN PATIENT SURVIVAL OF 12-15 MONTHS AND FIVE-YEAR SURVIVAL OF LESS THAN 5%. THE CURRENT STANDARD OF THERAPY FOR GBM COMPRISES SURGICAL RESECTION THEN RADIATION AND CHEMOTHERAPY. HOWEVER, DUE TO THE HETEROGENEITY AND INVASIVE NATURE OF GBM TUMOR CELLS THERE IS A HIGH RATE (~80%) OF TUMOR RECURRENCE, LEADING TO DISMAL SURVIVAL RATES THAT HAVE NOT CHANGED SIGNIFICANTLY IN OVER 50 YEARS. ONE OF THE PRIMARY HURDLES TO IMPROVING THESE OUT- COMES IS THE LACK OF RELIABLE AND ACCURATE MEANS TO MONITOR TUMOR PROGRESSION AND TREATMENT RESPONSE. THE CURRENT STANDARD METHODS OF TUMOR MONITORING, DIRECT TISSUE BIOPSY AND EXTERNAL IMAGING, ARE NOT ABLE TO SAFELY PROVIDE ACCURATE, FOCAL, LONGITUDINAL INFORMATION ABOUT THE TUMOR PROGRESSION AND TREATMENT RESPONSE THAT WOULD ALLOW CLINICIANS TO MODIFY TREATMENT REGIMEN TO IMPROVE SURVIVAL OUTCOMES. HERE WE PROPOSE THE TUMOR MONORAIL AS A PLATFORM THAT ALLOWS DIRECT, SERIAL ACCESS TO TUMOR MATERIAL, PROVIDING CRITICAL INFORMATION ABOUT TUMORS IN REAL TIME THAT WILL HELP CLINICIANS IMPROVE ACTIVE TREATMENT MANAGEMENT AND PATIENT SURVIVAL. THE TUMOR MONORAIL IS A BREAKTHROUGH DESIGNATED DEVICE AND HAS BEEN THE SUBJECT OF MULTIPLE FDA PRE-SUB- MISSION MEETINGS AND EXTENSIVE VERIFICATION AND BIOCOMPATIBILITY TESTING. BY LEVERAGING DESIGN AND MATERIAL SE- LECTIONS WITH A LONG HISTORY OF SAFE CLINICAL USE, THE TUMOR MONORAIL CAN SAFELY PROVIDE ACCESS TO THIS TYPICALLY INACCESSIBLE TUMOR IN AN OUTPATIENT SETTING. THIS WILL PROVIDE CLINICIANS WITH AN UNPRECEDENTED AMOUNT OF INFOR- MATION ABOUT TUMOR GENETICS AND TREATMENT RESPONSE IN REAL TIME THAT IS CRITICALLY IMPORTANT TO IMPROVING OUT- COMES FOR THE TREATMENT OF GBM. THE POTENTIAL IMPACT OF THIS PARADIGM SHIFTING DIAGNOSTIC TOOL IS WIDE RANGING, INCLUDING ENHANCING THE EFFICACY OF CURRENT STANDARD OF CARE AND NOVEL TREATMENT REGIMENS, INCREASING CLINICAL TRIAL EFFICIENCY BY ACCELERATING PATIENT PLACEMENT AND DATA COLLECTION, REMOVING UNCERTAINTY ABOUT TREATMENT EFFI- CACY AND TUMOR PROGRESSION INHERENT IN IMAGING, AND MORE. THE AIMS OF THIS PROPOSAL ARE FOCUSED ON OPTIMIZATION AND CLINICAL TRANSLATION OF THE TUMOR MONORAIL AS A PLAT- FORM FOR LONGITUDINAL GBM SAMPLING. IN THE PHASE 1 PORTION OF THE PROPOSAL WE WILL FIRST OPTIMIZE THE SAMPLING ABILITY AND CELLULAR MIGRATION IN THE DEVICE AND PERFORM MULTIPLE PRE-CLINICAL VERIFICATION TESTS THAT WILL IMPROVE USABILITY AND EASE REGULATORY APPROVAL. IN THE PHASE II PORTION WE WILL VALIDATE THE DEVICE EFFICACY IN CONCERT WITH STANDARD OF CARE TREATMENT IN A RODENT MODEL AND PERFORM MORE FDA REQUESTED PRE-CLINICAL TESTING THAT WILL CONFIRM LONG TERM EXPLANTABILITY, CLINICAL USABILITY, AND PREPARATION OF THE DEVICE FOR RAPID CLINICAL TRANSLATION. THESE ACTIVITIES WILL ENSURE THAT THE TUMOR MONORAIL IS WELL POSITIONED FOR SUBMISSION OF AN INVESTIGATIONAL DE- VICE EXEMPTION (IDE), CLINICAL TRANSLATION, AND RAPID ADOPTION TO PROVIDE A NEW TREATMENT PATH FOR GBM FOCUSED ON ACTIVE DISEASE MANAGEMENT AND INDIVIDUALLY TARGETED, RESPONSIVE TREATMENT THAT WOULD ALLOW CLINICIANS TO TAILOR INTERVENTIONS IN REAL TIME, INCREASING PATIENT OUTCOMES THAT HAVE BEEN STAGNANT FOR DECADES.
$2,397,615
PROJECT GRANT (B)
Mar 5, 2025
Level Eleven, LLC
384 Northyards Blvd Nw
Small Business Administration
7(A) LOAN GUARANTEES
AWARDTYPE: GUARANTEED/INSURED LOANS ACTIVITIES TO BE PERFORMED: TO PROVIDE GUARANTEED LOANS FROM LENDERS TO ELIGIBLE FOR PROFIT SMALL BUSINESSES WHICH ARE UNABLE TO OBTAIN FINANCING IN THE PRIVATE CREDIT MARKETPLACE BUT CAN DEMONSTRATE AN ABILITY TO REPAY LOANS IF GRANTED, IN A TIMELY MANNER. THE SBA GUARANTEES 7(A) PROGRAM LOANS THROUGH VARIOUS LOAN PROCESSING METHODS INCLUDING: (1) STANDARD 7(A) LOANS; (2) 7(A) SMALL LOANS; (3) SBAEXPRESS LOANS; (4) CAPLINE LOANS; (5) THE QUALIFIED EMPLOYEE TRUSTS (ESOP); (6) EXPORT EXPRESS; (7)EXPORT WORKING CAPITAL PROGRAM (EWCP); (8) INTERNATIONAL TRADE, AND (9) PILOT (TEMPORARY) PROGRAMS. DELIVERABLES: LOAN GUARANTEES EXPECTED OUTCOMES: TO PROVIDE GUARANTEED LOANS FROM LENDERS TO ELIGIBLE FOR PROFIT SMALL BUSINESSES AND, IN CERTAIN CIRCUMSTANCES, TO QUALIFIED EMPLOYEE TRUSTS (ESOPS). INTENDED BENEFICIARIES: SMALL BUSINESSES SUBRECIPIENT ACTIVITIES: NA
GUARANTEED/INSURED LOAN (F)
Jul 23, 2025
Level Eleven, LLC
384 Northyards Blvd Nw
Small Business Administration
7(A) LOAN GUARANTEES
AWARDTYPE: GUARANTEED/INSURED LOANS ACTIVITIES TO BE PERFORMED: TO PROVIDE GUARANTEED LOANS FROM LENDERS TO ELIGIBLE FOR PROFIT SMALL BUSINESSES WHICH ARE UNABLE TO OBTAIN FINANCING IN THE PRIVATE CREDIT MARKETPLACE BUT CAN DEMONSTRATE AN ABILITY TO REPAY LOANS IF GRANTED, IN A TIMELY MANNER. THE SBA GUARANTEES 7(A) PROGRAM LOANS THROUGH VARIOUS LOAN PROCESSING METHODS INCLUDING: (1) STANDARD 7(A) LOANS; (2) 7(A) SMALL LOANS; (3) SBAEXPRESS LOANS; (4) CAPLINE LOANS; (5) THE QUALIFIED EMPLOYEE TRUSTS (ESOP); (6) EXPORT EXPRESS; (7)EXPORT WORKING CAPITAL PROGRAM (EWCP); (8) INTERNATIONAL TRADE, AND (9) PILOT (TEMPORARY) PROGRAMS. DELIVERABLES: LOAN GUARANTEES EXPECTED OUTCOMES: TO PROVIDE GUARANTEED LOANS FROM LENDERS TO ELIGIBLE FOR PROFIT SMALL BUSINESSES AND, IN CERTAIN CIRCUMSTANCES, TO QUALIFIED EMPLOYEE TRUSTS (ESOPS). INTENDED BENEFICIARIES: SMALL BUSINESSES SUBRECIPIENT ACTIVITIES: NA
GUARANTEED/INSURED LOAN (F)
Apr 18, 2025
Exvade Bioscience INC
380 Northyards Blvd Nw
Department of Health and Human Services / National Institutes of Health
CANCER DETECTION AND DIAGNOSIS RESEARCH
TUMOR MONORAIL DEVICE FOR SERIAL GLIOBLASTOMA BIOPSY - PROJECT SUMMARY/ABSTRACT GLIOBLASTOMA (GBM) IS ONE OF THE MOST COMMON AND DEADLIEST FORM OF MALIGNANT BRAIN TUMORS, WITH MEDIAN PATIENT SURVIVAL OF 12-15 MONTHS AND FIVE-YEAR SURVIVAL OF LESS THAN 5%. THE CURRENT STANDARD OF THERAPY FOR GBM COMPRISES SURGICAL RESECTION THEN RADIATION AND CHEMOTHERAPY. HOWEVER, DUE TO THE HETEROGENEITY AND INVASIVE NATURE OF GBM TUMOR CELLS THERE IS A HIGH RATE (~80%) OF TUMOR RECURRENCE, LEADING TO DISMAL SURVIVAL RATES THAT HAVE NOT CHANGED SIGNIFICANTLY IN OVER 50 YEARS. ONE OF THE PRIMARY HURDLES TO IMPROVING THESE OUT- COMES IS THE LACK OF RELIABLE AND ACCURATE MEANS TO MONITOR TUMOR PROGRESSION AND TREATMENT RESPONSE. THE CURRENT STANDARD METHODS OF TUMOR MONITORING, DIRECT TISSUE BIOPSY AND EXTERNAL IMAGING, ARE NOT ABLE TO SAFELY PROVIDE ACCURATE, FOCAL, LONGITUDINAL INFORMATION ABOUT THE TUMOR PROGRESSION AND TREATMENT RESPONSE THAT WOULD ALLOW CLINICIANS TO MODIFY TREATMENT REGIMEN TO IMPROVE SURVIVAL OUTCOMES. HERE WE PROPOSE THE TUMOR MONORAIL AS A PLATFORM THAT ALLOWS DIRECT, SERIAL ACCESS TO TUMOR MATERIAL, PROVIDING CRITICAL INFORMATION ABOUT TUMORS IN REAL TIME THAT WILL HELP CLINICIANS IMPROVE ACTIVE TREATMENT MANAGEMENT AND PATIENT SURVIVAL. THE TUMOR MONORAIL IS A BREAKTHROUGH DESIGNATED DEVICE AND HAS BEEN THE SUBJECT OF MULTIPLE FDA PRE-SUB- MISSION MEETINGS AND EXTENSIVE VERIFICATION AND BIOCOMPATIBILITY TESTING. BY LEVERAGING DESIGN AND MATERIAL SE- LECTIONS WITH A LONG HISTORY OF SAFE CLINICAL USE, THE TUMOR MONORAIL CAN SAFELY PROVIDE ACCESS TO THIS TYPICALLY INACCESSIBLE TUMOR IN AN OUTPATIENT SETTING. THIS WILL PROVIDE CLINICIANS WITH AN UNPRECEDENTED AMOUNT OF INFOR- MATION ABOUT TUMOR GENETICS AND TREATMENT RESPONSE IN REAL TIME THAT IS CRITICALLY IMPORTANT TO IMPROVING OUT- COMES FOR THE TREATMENT OF GBM. THE POTENTIAL IMPACT OF THIS PARADIGM SHIFTING DIAGNOSTIC TOOL IS WIDE RANGING, INCLUDING ENHANCING THE EFFICACY OF CURRENT STANDARD OF CARE AND NOVEL TREATMENT REGIMENS, INCREASING CLINICAL TRIAL EFFICIENCY BY ACCELERATING PATIENT PLACEMENT AND DATA COLLECTION, REMOVING UNCERTAINTY ABOUT TREATMENT EFFI- CACY AND TUMOR PROGRESSION INHERENT IN IMAGING, AND MORE. THE AIMS OF THIS PROPOSAL ARE FOCUSED ON OPTIMIZATION AND CLINICAL TRANSLATION OF THE TUMOR MONORAIL AS A PLAT- FORM FOR LONGITUDINAL GBM SAMPLING. IN THE PHASE 1 PORTION OF THE PROPOSAL WE WILL FIRST OPTIMIZE THE SAMPLING ABILITY AND CELLULAR MIGRATION IN THE DEVICE AND PERFORM MULTIPLE PRE-CLINICAL VERIFICATION TESTS THAT WILL IMPROVE USABILITY AND EASE REGULATORY APPROVAL. IN THE PHASE II PORTION WE WILL VALIDATE THE DEVICE EFFICACY IN CONCERT WITH STANDARD OF CARE TREATMENT IN A RODENT MODEL AND PERFORM MORE FDA REQUESTED PRE-CLINICAL TESTING THAT WILL CONFIRM LONG TERM EXPLANTABILITY, CLINICAL USABILITY, AND PREPARATION OF THE DEVICE FOR RAPID CLINICAL TRANSLATION. THESE ACTIVITIES WILL ENSURE THAT THE TUMOR MONORAIL IS WELL POSITIONED FOR SUBMISSION OF AN INVESTIGATIONAL DE- VICE EXEMPTION (IDE), CLINICAL TRANSLATION, AND RAPID ADOPTION TO PROVIDE A NEW TREATMENT PATH FOR GBM FOCUSED ON ACTIVE DISEASE MANAGEMENT AND INDIVIDUALLY TARGETED, RESPONSIVE TREATMENT THAT WOULD ALLOW CLINICIANS TO TAILOR INTERVENTIONS IN REAL TIME, INCREASING PATIENT OUTCOMES THAT HAVE BEEN STAGNANT FOR DECADES.
$2,397,615
PROJECT GRANT (B)
Sep 26, 2024

Schools & Education

Part of Atlanta City School District. 3 nearby schools serving this area.

E
Elementary

Thomas Heathe Slater Elementary School

Score 16/100
Enrollment 570
Distance 0.4 mi
M
Middle

Judson Price Middle School

Score 16/100
Enrollment 303
Distance 0.6 mi
H
High School

Carver High School

Distance 0.5 mi

Source: National Center for Education Statistics (NCES) · Updated Feb 2026

At a Glance

Avg Home Value
$23,259,067
Est. Monthly Cost
$127,301
$117,610 mortgage · N/A tax
Best School
16/100
3 nearby schools
Stability
Stable
55/100
3 homes · 1 street

Northyards Blvd exhibits moderate stability with a mix of long-term and newer residents.

Continue Your Research

Frequently Asked Questions

What is the average home value in Northyards Blvd?
Property data for Northyards Blvd includes commercial parcels. Individual property details are available in the directory below.
What school district is Northyards Blvd in?
Northyards Blvd is served by Atlanta City School District. The highest-rated nearby school scores 16/100.
How many homes are in Northyards Blvd?
Northyards Blvd in Atlanta, GA has 3 homes across 1 street.
Is Northyards Blvd good for families?
Northyards Blvd is served by Atlanta City School District (top school score: 16/100), average home value of $23,259,067. The neighborhood has 3 homes across 1 street, providing a close-knit community for families.
How much does it cost to live in Northyards Blvd?
The average assessed home value is $23,259,067, and the estimated total monthly housing cost (mortgage, taxes, and insurance) is approximately $127,301. These estimates are based on a 30-year mortgage at 6.5% with 20% down.
What elementary school serves Northyards Blvd?
The nearest elementary school is Thomas Heathe Slater Elementary School, located 0.4 miles away. It has 570 students enrolled.
What high school serves Northyards Blvd?
The nearest high school is Carver High School, located 0.5 miles away.
Is Northyards Blvd a stable neighborhood?
Northyards Blvd has a stability score of 55/100, classified as "Stable." This indicates moderate stability with some residential turnover.

Data Sources & Methodology

6 verified data sources power this report

Property tax & valuation records

Federal education statistics

Healthcare facility & outcome data

Transportation & hazard data

5-year community survey estimates

Housing market indicators

Last updated:

View full methodology

Get Neighborhood Updates

Stay informed about changes in Northyards Blvd.